Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
26.88
+0.62 (2.36%)
Nov 14, 2024, 4:00 PM EST - Market closed
Tourmaline Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 24.36 | 13.04 | 2.18 | 0.69 |
| Research & Development | 54.46 | 32.37 | 17.53 | 0.21 |
| Operating Expenses | 78.82 | 45.41 | 19.7 | 0.9 |
| Operating Income | -78.82 | -45.41 | -19.7 | -0.9 |
| Other Non Operating Income (Expenses) | 14.94 | 3.29 | - | - |
| Pretax Income | -63.88 | -42.12 | -19.7 | -0.9 |
| Net Income | -63.88 | -42.12 | -19.7 | -0.9 |
| Net Income to Common | -63.88 | -42.12 | -19.7 | -0.9 |
| Shares Outstanding (Basic) | 23 | 5 | 1 | 11 |
| Shares Outstanding (Diluted) | 23 | 5 | 1 | 11 |
| Shares Change (YoY) | 16.90% | 441.28% | -91.94% | - |
| EPS (Basic) | -2.79 | -8.87 | -22.46 | -0.08 |
| EPS (Diluted) | -2.79 | -8.87 | -22.46 | -0.08 |
| Free Cash Flow | -65.73 | -28.14 | -6.53 | - |
| Free Cash Flow Per Share | -2.87 | -5.93 | -7.44 | - |
| EBITDA | -78.78 | -45.38 | -19.7 | - |
| D&A For EBITDA | 0.04 | 0.03 | 0.01 | - |
| EBIT | -78.82 | -45.41 | -19.7 | -0.9 |
Source: S&P Capital IQ. Standard template.
Financial Sources.